Molly Gallogly

1.9k total citations
40 papers, 1.5k citations indexed

About

Molly Gallogly is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Molly Gallogly has authored 40 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 16 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Molly Gallogly's work include Chronic Lymphocytic Leukemia Research (7 papers), Acute Myeloid Leukemia Research (7 papers) and CAR-T cell therapy research (6 papers). Molly Gallogly is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Acute Myeloid Leukemia Research (7 papers) and CAR-T cell therapy research (6 papers). Molly Gallogly collaborates with scholars based in United States, Italy and Philippines. Molly Gallogly's co-authors include John J. Mieyal, Suparna Qanungo, Melissa D. Shelton, David W. Starke, Brenda Cooper, Hillard M. Lazarus, Marcos de Lima, Shine Raju, Sumanth Khadke and M. Rizwan Sohail and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biochemistry.

In The Last Decade

Molly Gallogly

37 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Molly Gallogly United States	12	1.0k	398	220	129	121	40	1.5k
Takahito Kondo Japan	22	690 0.7×	212 0.5×	153 0.7×	84 0.7×	168 1.4×	51	1.4k
Geumsoo Kim United States	17	839 0.8×	157 0.4×	151 0.7×	83 0.6×	61 0.5×	37	1.3k
Margareta Berggren United States	12	1.1k 1.0×	202 0.5×	125 0.6×	182 1.4×	145 1.2×	17	1.6k
Zheng-Zheng Shi United States	19	637 0.6×	223 0.6×	116 0.5×	44 0.3×	90 0.7×	26	984
Hector A. Bergonia United States	14	570 0.5×	220 0.6×	487 2.2×	49 0.4×	32 0.3×	26	1.1k
Wai‐Nang Paul Lee United States	19	831 0.8×	159 0.4×	142 0.6×	61 0.5×	129 1.1×	28	1.4k
Geetha M. Habib United States	17	1.3k 1.2×	568 1.4×	180 0.8×	93 0.7×	131 1.1×	30	2.0k
De Lin United States	14	527 0.5×	106 0.3×	204 0.9×	69 0.5×	90 0.7×	23	1.1k
Andrew C. Lake United States	11	542 0.5×	196 0.5×	218 1.0×	64 0.5×	267 2.2×	20	1.5k
Thomas J. Carty United States	21	561 0.5×	201 0.5×	171 0.8×	59 0.5×	133 1.1×	41	1.5k

Countries citing papers authored by Molly Gallogly

Since Specialization

Citations

This map shows the geographic impact of Molly Gallogly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Molly Gallogly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Molly Gallogly more than expected).

Fields of papers citing papers by Molly Gallogly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Molly Gallogly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Molly Gallogly. The network helps show where Molly Gallogly may publish in the future.

Co-authorship network of co-authors of Molly Gallogly

This figure shows the co-authorship network connecting the top 25 collaborators of Molly Gallogly. A scholar is included among the top collaborators of Molly Gallogly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Molly Gallogly. Molly Gallogly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dong, Qianze, Shashirekha Shetty, Yang Wang, et al.. (2024). Philadelphia chromosome-positive T-cell acute lymphoblastic leukemia: a case report. Journal of International Medical Research. 52(2).

Wang, Jiasheng, Amin Firoozmand, Pingfu Fu, et al.. (2023). Phase I study of intra-osseous co-transplantation of a single-unit cord blood and mesenchymal stromal cells with reduced intensity conditioning regimens. Frontiers in Oncology. 13. 1186532–1186532. 2 indexed citations

Caimi, Paolo F., Amanda F. Cashen, Molly Gallogly, et al.. (2023). Venetoclax combined with R‐ICE (VICER) for second line treatment of diffuse large B cell lymphoma refractory or relapsed after initial chemoimmunotherapy. Hematological Oncology. 41(S2). 436–437. 1 indexed citations

Otegbeye, Folashade, Brenda Cooper, Paolo F. Caimi, et al.. (2022). A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors. Transplantation and Cellular Therapy. 28(5). 250.e1–250.e8. 19 indexed citations

Abedin, Sameem, Mehdi Hamadani, Shernan G. Holtan, et al.. (2022). Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD). Blood. 140(Supplement 1). 10495–10497. 7 indexed citations

Diamond, Akiva, Kirsten M Boughan, Brenda Cooper, et al.. (2021). Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates. Clinical Lymphoma Myeloma & Leukemia. 21(11). 799–804. 2 indexed citations

Wang, Jiasheng, Marcos de Lima, Matthew Cooper, et al.. (2021). Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia. Leukemia & lymphoma. 62(6). 1450–1457. 2 indexed citations

Khadke, Sumanth, Nausheen Ahmed, Shine Raju, et al.. (2020). Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virology Journal. 17(1). 154–154. 70 indexed citations

Metheny, Leland, Ronald Sobecks, Navneet S. Majhail, et al.. (2020). Inotuzumab Ozogamicin Post-Transplant for Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 26(3). S122–S123. 1 indexed citations

10.

Cao, Shufen, Suchitra Sundaram, Sabarish Ayyappan, et al.. (2020). Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma ‐ specific venous thrombosis prediction models. American Journal of Hematology. 95(8). 918–926. 12 indexed citations

11.

Tomlinson, Benjamin, Molly Gallogly, Leland Metheny, et al.. (2019). A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. Clinical Lymphoma Myeloma & Leukemia. 20(4). 226–233.e1. 19 indexed citations

12.

Caimi, Paolo F., Deepa Jagadeesh, Kirsten M Boughan, et al.. (2018). Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study. Blood. 132(Supplement 1). 397–397. 6 indexed citations

13.

Cooper, Brenda, Paolo F. Caimi, Ehsan Malek, et al.. (2018). Vascular Access and Bloodstream Infections Associated with Tunneled, Non-Trialysis and Non-Tunneled, Trialysis Catheters in Patients Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 24(3). S311–S312.

14.

Martin, Petra, Kirsten M Boughan, Brenda Cooper, et al.. (2018). Leukocyte Subtypes As Predictors for Venous Thromboembolism in Diffuse Large B-Cell Lymphoma. Blood. 132(Supplement 1). 495–495. 1 indexed citations

15.

Gallogly, Molly, Paolo F. Caimi, Michael Craig, et al.. (2017). A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia. Blood. 130. 1332–1332. 4 indexed citations

16.

Gallogly, Molly, Alexander E. Perl, & Hillard M. Lazarus. (2017). Midostaurin and emerging FLT3 inhibitors for the treatment of adults with newly diagnosed acute myeloid leukemia with the FLT3 mutation. Expert Review of Precision Medicine and Drug Development. 2(6). 307–320. 1 indexed citations

17.

Zhu, Xiaochun, Molly Gallogly, John J. Mieyal, Vernon Anderson, & Lawrence M. Sayre. (2009). Covalent Cross-Linking of Glutathione and Carnosine to Proteins by 4-Oxo-2-nonenal. Chemical Research in Toxicology. 22(6). 1050–1059. 37 indexed citations

18.

Gallogly, Molly, Melissa D. Shelton, Suparna Qanungo, et al.. (2009). Glutaredoxin Regulates Apoptosis in Cardiomyocytes via NFκB Targets Bcl-2 and Bcl-xL: Implications for Cardiac Aging. Antioxidants and Redox Signaling. 12(12). 1339–1353. 65 indexed citations

19.

Mieyal, John J., et al.. (2008). Molecular Mechanisms and Clinical Implications of Reversible Protein S -Glutathionylation. Antioxidants and Redox Signaling. 10(11). 1941–1988. 454 indexed citations

20.

Gallogly, Molly & John J. Mieyal. (2007). Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Current Opinion in Pharmacology. 7(4). 381–391. 389 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact